A market report on hemp-derived CBD’s growing interest to be used in personal care and cosmetics, regulatory changes and natural and plant-based wellness products.
Image | adobe.stock/Chaosamran_Studio
A recent report called “Hemp-derived Cannabidiol Market by Product, by Application, by End-User, and By Region” was recently published on ResearchAndMarkets.com(1,2). According to that report, in 2023, the global hemp-derived cannabidiol (CBD) market size reached an estimated $8.28 billion and is anticipated to hit $46.25 billion by 2034 (1). With this growth, the category will have a compound annual growth rate (CAGR) of 16.93% during a projected forecast period from 2024-2034(1).
The data disclosed in the report showcased a rising interest for CBD’s use in cosmetics and other personal care products. It recognizes a positive change as consumers are growing more accepting of CBD. With the shift seen in consumers, this could lead to further research and development of new products and changes in regulations to better benefit hemp and CBD products (1). Consumers are also becoming more interested in natural and plant-based wellness products.
According to the report (1), CBD is considered to be a “natural alternative” to traditional pharmaceuticals for various health ailments such as, inflammation, stress, and pain. In 2023, the hemp-derived CBD distillate segment was the highest revenue-grossing segment in the global hemp-derived CBD market. This was mainly due to the expansive amount of other terpenes and cannabinoids that can be found (1). The presence of these other components allows for the use of CBD distillates in other products such as topicals, edibles, and tinctures. With the growing demand for CBD, the hemp-derived CBD isolate segment is also expected to see its fastest CAGR, during the 2024-2034 forecast period.
While CBD and other hemp cannabinoids operate in a regulatory gray area, there has been some efforts in Congress to change the ingredient's status so that it can be regulated more effectively. The report cites the Cannabinoid Safety and Regulation Act (CSRA) introduced in October 2024 by Senator Ron Wyden (OR) as the most recent example of this(1).
In terms of product application, the anxiety segment is the highest revenue-grossing segment, while the atopic dermatitis segment is anticipated to increase during the forecast period to its fastest CAGR (1). This is being witnessed from heightened use in consumers for CBD skincare products to be used for health conditions such as, eczema and dermatitis. As such, another segment seeing high revenue is personal care and cosmetics (1). As a result of increased use of CBD in beauty products, by end user the personal care and cosmetics segment was the highest revenue-grossing segment in the global hemp-derived CBD market (1). CBD potentially holds benefits in anti-aging, anti-inflammatory, and antioxidants. With these properties, CBD can be highly sought after in a variety of beauty products.
The press release showcases some of the highlights from the “Hemp-derived Cannabidiol Market by Product, by Application, by End-User, and By Region” report which targeted global and regional market sizes and forecasts during the time period of 2023 to 2034.(1,2):
Report Scope:
Report Segmentation:
Hemp-derived Cannabidiol Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
Hemp-derived Cannabidiol Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
Hemp-derived Cannabidiol Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
To learn more about this report please click here.
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.